Streptavidin in antibody pretargeting. 5. Chemical modification of recombinant streptavidin for labeling with the α-particle-emitting radionuclides 213Bi and 211At

Bioconjugate Chemistry

Volumn 19, Issue 1, 2008, Pages 158-170

  Wilbur, D Scott ^a   Hamlin, Donald K ^a   Chyan, Ming Kuan ^a   Brechbiel, Martin W ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; BISMUTH 213; CARBORANE DERIVATIVE; OXIDIZING AGENT; PENTETIC ACID; RECOMBINANT STREPTAVIDIN; RECOMBINANT STREPTAVIDIN AT 211; RECOMBINANT STREPTAVIDIN BI 213; RECOMBINANT STREPTAVIDIN I 125; STREPTAVIDIN; SUCCINIC ANHYDRIDE; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHELATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG LABELING; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; NUDE MOUSE; RADIOISOTOPE DISTRIBUTION; TISSUE DISTRIBUTION;

MUS;

EID: 38949108271     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc7002428     Document Type: Article

References (72)

1. Mulford, D. A., Scheinberg, D. A., and Jurcic, J. G. (2005) The promise of targeted α-particle therapy. J. Nucl. Med. 46, 199S-204S.
2. Couturier, O., Supiot, S., Degraef-Mougin, M., Faivre-Chauvet, A., Carlier, T., Chatal, J. F., Davodeau, F., and Cherel, M. (2005) Cancer radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. Mol. Imaging 32, 601-614.
3. Imam, S. K. (2001) Advancements in cancer therapy with alpha-emitters: a review. Int. J. Radiat. Oncol. Biol. Phys. 51, 271-278.
4. Zalutsky, M. R., and Vaidyanathan, G. (2000) Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr. Pharm. Des. 6, 1433-1455.
5. Feinendegen, L. E., and McClure, J. J. (1997) Alpha-emitters for medical therapy: workshop of the United States Department of Energy. Radiat. Res. 148, 195-201.
6. Goldenberg, D. M. (2002) Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 43, 693-713.
7. 125I](Z)-3-methoxy- 17α-iodovinylestra-1,3,5(10),6-tetraen-17β-ol. Appl. Radiat. Isot. 54, 227-239.
8. Stinchcomb, T. G., and Roeske, J. C. (1992) Analytic microdosimetry for radioimmunotherapeutic alpha emitters. Med. Phys. 19, 1385-1393.
9. Li, L., Yazaki, P. J., Anderson, A. L., Crow, D., Colcher, D., Wu, A. M., Williams, L. E., Wong, J. Y., Raubitschek, A., and Shively, J. E. (2006) Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjugate Chem. 17, 68-76.
10. Kobayashi, H., Le, N., Kim, I. S., Kim, M. K., Pie, J. E., Drumm, D., Paik, D. S., Waldmann, T. A., Paik, C. H., and Carrasquillo, J. A. (1999) The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res. 59, 422-430.
11. Fu, P. P., Unruh, L. E., Miller, D. W., Huang, L. W., and Yang, D. T. C. (1985) Synthesis of 3-Aryl-3,4-dihydroisocoumarins. J. Org. Chem. 50, 1259-1261.
12. Fujioka, Y., Satake, S., Uehara, T., Mukai, T., Akizawa, H., Ogawa, K., Saji, H., Endo, K., and Arano, Y. (2005) In vitro system to estimate renal brush border enzyme-mediated cleavage of peptide linkages for designing radiolabeled antibody fragments of low renal radioactivity levels. Bioconjugate Chem. 16, 1610-1616.
13. Behe, M., Becker, W., Gotthardt, M., Angerstein, C., and Behr, T. M. (2003) Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur. J. Nucl. Med. Mol. Imaging 30, 1140-1146.
14. Goodwin, D. A., and Meares, C. F. (1997) Pretargeting: general principles. Cancer 80, 2675-2680.
15. Zhu, H., Jain, R. K., and Baxter, L. T. (1998) Tumor Pretargeting for radioimmunodetection and radioimmunotherapy. J. Nucl. Med. 39, 65-76.
16. Wilbur, D. S., Stayton, P. S., To, R., Buhler, K. R., Klumb, L. A., Hamlin, D. K., Stray, J. E., and Vessella, R. L. (1998) Streptavidin in antibody pretargeting. Comparison of a recombinant streptavidin with two streptavidin mutant proteins and two commercially available streptavidin proteins. Bioconjugate Chem. 9, 100-107.
17. Wilbur, D. S., Hamlin, D. K., Buhler, K. R., Pathare, P. M., Vessella, R. L., Stayton, P. S., and To, R. (1998) Streptavidin in antibody pretargeting. 2. Evaluation of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity. Bioconjugate Chem. 9, 322-330.
18. Wilbur, D. S., Hamlin, D. K., Meyer, D. L., Mallett, R. W., Quinn, J., Vessella, R. L., and Press, O. W. (2002) Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin. Bioconjugate Chem. 13, 611-620.
19. Wilbur, D. S., Hamlin, D. K., Sanderson, J., and Lin, Y. (2004) Streptavidin in antibody pretargeting. 4. Site-directed mutation provides evidence that both arginine and lysine residues are involved in kidney localization. Bioconjugate Chem. 15, 1454-1463.
20. Sandmaier, B. M., Bethge, W. A., Wilbur, D. S., Hamlin, D. K., Santos, E. B., Brechbiel, M. W., Fisher, D. R., and Storb, R. (2002) Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 100, 318-326.
21. Bethge, W. A., Wilbur, D. S., Storb, R., Hamlin, D. K., Santos, E. B., Brechbiel, M. W., Fisher, D. R., and Sandmaier, B. M. (2003) Selective T-cell ablation with bismuth-213-labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 101, 5068-5075.
22. Camera, L., Kinuya, S., Garmestani, K., Wu, C., Brechbiel, M. W., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H., and Carrasquillo, J. A. (1994) Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J. Nucl. Med. 35, 882-889.
23. Milenic, D. E., Roselli, M., Mirzadeh, S., Pippin, C. G., Gansow, O. A., Colcher, D., Brechbiel, M. W., and Schlom, J. (2001) In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biother. Radiopharm. 16, 133-146.
24. Adams, G. P., Shaller, C. C., Chappell, L. L., Wu, C., Horak, E. M., Simmons, H. H., Litwin, S., Marks, J. D., Weiner, L. M., and Brechbiel, M. W. (2000) Delivery of the α-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl. Med. Biol. 27, 339-346.
25. Nikula, T. K., McDevitt, M. R., Finn, R. D., Wu, C., Kozak, R. W., Garmestani, K., Brechbiel, M. W., Curcio, M. J., Pippin, C. G., Tiffany-Jones, L., Geerlings, M. W., Sr., Apostolidis, C., Molinet, R., Geerlings, M. W., Jr., Gansow, O. A., and Scheinberg, D. A. (1999) Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med. 40, 166-176.
26. McDevitt, M. R., Finn, R. D., Ma, D., Larson, S. M., and Scheinberg, D. A. (1999) Preparation of alpha-emitting 213 Bi-labeled antibody constructs for clinical use. J. Nucl. Med. 40, 1722-1727.
27. Vaughan, A. T. M., and Fremlin, J. H. (1978) The preparation of astatine labelled proteins using an electrophilic reaction. Int. J. Nucl. Med. Biol. 5, 229-230.
28. 211At labelled monoclonal antibody with known specificity in a murine system. Int. J. Radiat. Oncol. Biol. Phys. 8, 1943-1946.
29. Zalutsky, M. R., and Narula, A. S. (1988) Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Appl. Radiat. Isot. 39, 227-232.
30. 125I]iodobenzoyl conjugate. Bioconjugate Chem. 2, 171-179.
31. Wilbur, D. S., Chyan, M.-K., Hamlin, D. K., Vessella, R. L., Wedge, T. J., and Hawthorne, M. F. (2007) Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination. Bioconjugate Chem. 18, 1226-1240.
32. 2. Nucl. Med. Biol. 20, 917-927.
33. Lindegren, S., Back, T., and Jensen, H. J. (2001) Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl. Radiat. Isot. 55, 157-160.
34. Brechbiel, M. W., and Gansow, O. A. (1992) Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter. J. Chem. Soc., Perkin Trans. 1, 1173-1178.
35. Wilbur, D. S., Chyan, M. K., Hamlin, D. K., Kegley, B. B., Risler, R., Pathare, P. M., Quinn, J., Vessella, R. L., Foulon, C., Zalutsky, M., Wedge, T. J., and Hawthorne, M. F. (2004) Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. Bioconjugate Chem. 15, 203-223.
36. Hamblett, K. J., Kegley, B. B., Hamlin, D. K., Chyan, M. K., Hyre, D. E., Press, O. W., Wilbur, D. S., and Stayton, P. S. (2002) A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. Bioconjugate Chem. 13, 588-98.
37. Pippin, C. G., Parker, T. A., McMurry, T. J., and Brechbiel, M. W. (1992) Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjugate Chem. 3, 342-345.
38. Bethge, W. A., Wilbur, D. S., Storb, R., Hamlin, D. K., Santos, E. B., Brechbiel, M. W., and Sandmaier, B. M. (2004) Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study. Transplantation 78, 352-359.
39. Kaplan, H. M., Brewer, N. R., and Blair, W. H. (1983) The Mouse in Biomedical Research, in The Mouse in Biomedical Research (Foster, H. L., Small, J. D., and Fox, J. G., Eds.) pp 248-292, Academic Press, New York.
40. Hamilton, J. G., Asling, C. W., Garrison, W. M., and Scott, K. G. (1953) The accumulation, metabolism and biological effects of astatine in rats and monkeys. Univ. Calif. Publ. Pharmacol. 2, 283-343.
41. Bray, L. A., Tingey, J. M., DesChane, J. R., Egorov, O. B., Tenforde, T. S., Wilbur, D. S., Hamlin, D. K., and Pathare, P. M. (2000) Development of a unique bismuth (Bi-213) automated generator for use in cancer therapy. Ind. Eng. Chem. Res. 39, 3189-3194.
42. 211At-labeled antibodies for clinical use. J. Nucl. Med. 42, 1508-1515.
43. 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Cli. Exp. Metastasis 22, 575-586.
44. 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother. Radiopharm. 19, 135-147.
45. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 60, 6095-6100.
46. 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res. 59, 2635-2643.
47. 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res. 66, 8227-8232.
48. Elgqvist, J., Andersson, H., Back, T., Hultborn, R., Jensen, H., Karlsson, B., Lindegren, S., Palm, S., Warnhammar, E., and Jacobsson, L. (2005) Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. J. Nucl. Med. 46, 1907-1915.
49. Paganelli, G., Malcovati, M., and Fazio, F. (1991) Monoclonal Antibody pretargetting techniques for tumour localization: the avidin-biotin system. Nucl. Med. Commun. 12, 211-234.
50. Pagel, J. M., Hedin, N., Subbiah, K., Meyer, D., Mallet, R., Axworthy, D., Theodore, L. J., Wilbur, D. S., Matthews, D. C., and Press, O. W. (2003) Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 101, 2340-2348.
51. Pagel, J. M., Lin, Y., Hedin, N., Pantelias, A., Axworthy, D., Stone, D., Hamlin, D. K., Wilbur, D. S., and Press, O. W. (2006) Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. Blood 108, 328-336.
52. Press, O. W., Corcoran, M., Subbiah, K., Hamlin, D. K., Wilbur, D. S., Johnson, T., Theodore, L., Yau, E., Mallett, R., Meyer, D. L., and Axworthy, D. (2001) A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98, 2535-2543.
53. Axworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F., Hobson, L. J., Beaumier, P. L., and Fritzberg, A. R. (2000) Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. U.S.A. 97 1802-1807.
54. Zhang, M., Yao, Z., Garmestani, K., Axworthy, D. B., Zhang, Z., Mallett, R. W., Theodore, L. J., Goldman, C. K., Brechbiel, M. W., Carrasquillo, J. A., and Waldmann, T. A. (2002) Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213. Blood 100, 208-216.
55. Zhang, M., Yao, Z., Saga, T., Sakahara, H., Nakamoto, Y., Sato, N., Nakada, H., Yamshina, I., and Konishi, J. (1998) Improved intratumoral penetration of radiolabeled streptavidin in intraperitoneal tumors pretargeted with biotinylated antibody. J. Nucl. Med. 39, 30-33.
56. Maraveyas, A., RowlinsonBusza, G., Murray, S., and Epenetos, A. A. (1998) Improving tumour targeting and decreasing normal tissue uptake by optimizing the stoichiometry of a two-step biotinylated-antibody/streptavidin-based targeting strategy: Studies in a nude mouse xenograft model. Int. J. Cancer 78, 610-617.
57. Saga, T., Weinstein, J. N., Jeong, J. M., Heya, T., Lee, J. T., Le, N., Paik, C. H., Sung, C., and Neumann, R. D. (1994) Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res. 54, 2160-2165.
58. Paganelli, G., Pervez, S., Siccardi, A. G., Rowlinson, G., Deleide, G., Chiolerio, F., Malcovati, M., Scassellati, G. A., and Epenetos, A. A. (1990) Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int. J. Cancer 45, 1184-1189.
59. 213Bi, and their decay chain related radionuclides, for therapeutic applications. Chem. Rev. 101, 2019-2036.
60. Zidenberg-Cherr, S., Parks, N. J., and Keen, C. L. (1987) Tissue and subcellular distribution of bismuth radiotracer in the rat: considerations of cytotoxicity and microdosimetry for bismuth radiopharmaceuticals. Radiat. Res. 111, 119-129.
61. Kobayashi, H., Wu, C. C., Yoo, T. M., Sun, B. F., Drumm, D., Pastan, I., Paik, C. H., Gansow, O. A., Carrasquillo, J. A., and Brechbiel, M. W. (1998) Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J. Nucl. Med. 39, 829-836.
62. Roselli, M., Milenic, D. E., Brechbiel, M. W., Mirzadeh, S., Pippin, C. G., Gansow, O. A., Colcher, D., and Schlom, J. (1999) In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts. Cancer Biother. Radiopharm. 14, 209-220.
63. Chen, J. Q., Strand, S. E., Brechbiel, M. W., Gansow, O. A., and Sjoegren, H. O. (1996) Combination of biotinylation and indium-111 labeling with chelate SCN-Bz-CHX-A-DTPA for chimeric BR96: Biodistribution and pharmacokinetic studies in colon carcinoma isografted rats. Tumor Targeting 2, 66-75.
64. 212Bi) therapy. Cancer Res. 53, 5683-5689.
65. Caliceti, P., Chinol, M., Roldo, M., Veronese, F. M., Semenzato, A., Salmaso, S., and Paganelli, G. (2002) Polyethylene glycol)-avidin bioconjugates: suitable candidates for tumor pretargeting. J. Controlled Release 83, 97-108.
66. Salmaso, S., Semenzato, A., Bersania, S., Chinol, M., Paganelli, G., and Caliceti, P. (2005) Preparation and characterization of active site protected poly(ethyleneglycol)-avidin bioconjugates. Biochim. Biophys. Acta 1726, 57-66.
67. Smit, J. A., Myburgh, J. A., and Neirinckx, R. D. (1973) Specific inactivation of sensitized lymphocytes in vitro using antigens labelled with astatine-211. Clin. Exp. Immunol. 14, 107-116.
68. Aaij, C., Tschroots, W. R. J. M., Lindner, L., and Feltkamp, T. E. W. (1975) The preparation of astatine labelled proteins. Int. J. Appl. Radiat. Isot. 26, 25-30.
69. Visser, G. W. M., Diemer, E. L., and Kaspersen, F. M. (1981) The nature of the astatine-protein bond. Int. J. Appl. Radiat. Isot. 32, 905-912.
70. Visser, G. W. M., Diemer, E. L., and Kaspersen, F. M. (1979) The preparation and stability of astatotyrosine and astatoiodotyrosine. Int. J. Appl. Radiat. Isot. 30, 749-752.
71. Savage, M. D., Mattson, G., Desai, S., Nielander, G. W., Morgensen, S., and Conklin, E. J. (1992) Avidin-Biotin Chemistry: A Handbook, Pierce Chemical Company, Rockford, IL.
72. Vaughan, A. T. M., and Fremlin, J. H. (1977) The preparation of astatotyrosine. Int. J. Appl. Radiat. Isot. 28, 595-598.